| Literature DB >> 27660690 |
Yikai Wang1, Jean-Yves Wach1, Patrick Sheehan1, Cheng Zhong1, Chenyang Zhan2, Richard Harris2, Steven C Almo2, Joshua Bishop3, Stephen J Haggarty3, Alexander Ramek1, Kayla N Berry1, Conor O'Herin1, Angela N Koehler1, Alvin W Hung1, Damian W Young1.
Abstract
Traditional fragment-based drug discovery (FBDD) relies heavily on structural analysis of the hits bound to their targets. Herein, we present a complementary approach based on diversity-oriented synthesis (DOS). A DOS-based fragment collection was able to produce initial hit compounds against the target GSK3β, allow the systematic synthesis of related fragment analogues to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compound.Entities:
Keywords: Diversity oriented synthesis; GSK3β; fragment growing; fragment-based drug discovery
Year: 2016 PMID: 27660690 PMCID: PMC5018862 DOI: 10.1021/acsmedchemlett.6b00230
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345